Mile High Labs International Limited provides a brief introduction to a brand-new industry, CBD, a non-psychoactive cannabinoid
The United States (U.S.) is in the midst of a hemp revolution, thanks in part to last year’s Agricultural Improvement Act of 2018 (commonly known as the 2018 Farm Bill) that paved the way for legal production. Today, across the U.S., hemp is grown to produce CBD, a non-psychoactive cannabinoid that has become one of the most talked about and least understood ingredients in the marketplace.
Recently, the U.S. Food and Drug Administration held a public hearing to determine a pathway toward regulating CBD and was struggling to bring its regulatory framework to where it needs to be, in the wake of a massive increase in sales. In the United Kingdom, while we are somewhat earlier in the rapidly growing market (where sales are projected to be worth some $22 billion within three years), CBD sales have reached over 250,000 consumers in the UK, double the figure for the previous year.
It appears that CBD is everywhere. In America, the CBD industry is booming and in Europe, there are more questions than answers. What is CBD? How can you be sure it’s safe? What does a European CBD market look like?
Who is Mile High Labs?
Mile High Labs is an industrial-scale CBD ingredient manufacturer offering a reliable delivery of bulk CBD (and private labelling services to the world’s leading consumer brands). With a GMP certified extraction facility and an extensive network of contracted cultivators, Mile High Labs supplies high-quality, high-volume CBD orders year round.
Mile High Labs is headquartered in Boulder, Colorado and operates offices and distribution centres in the U.S. and Europe. From a European perspective, there may be misunderstandings around the company brand name. The name Mile High Labs is derived from the fact that Denver is known as the “Mile High City” as it is exactly 5,280 feet above sea level. The city’s American football team plays at Mile High Stadium and throughout the state, there is everything from auto dealerships to churches with “mile high” in their name.
What is CBD?
CBD is short for cannabidiol and is extracted from industrial hemp. It is a cousin of the Marijuana plant. Although they look similar, their properties are very different. Simply put, CBD doesn’t get you high.
The hemp is harvested and processed to extract the cannabinoids, of which CBD is one of many. At Mile High Labs, we refine the CBD one step further by separating it from the other cannabinoids. This finished product is “isolate,” a white, almost odourless and flavourless powder that resembles cornflour or icing sugar and is greater than 98% pure CBD.
Because we are isolating the CBD molecule, our product contains no THC. It’s compliant, safe and highly versatile. We can qualify its purity and cannabinoid content, allowing us to confidently ship it to open markets across the world.
New technology for better safety
CBD isolate is a significantly refined, highly concentrated premium product. To ensure the safety of the product, Mile High Labs uses blockchain technology to track the isolate from field to sale. The blockchain creates a digital paper trail of every human interaction with the product. The resulting data is unalterable and serves as the isolate’s pedigree.
“Blockchain technology helps us aggregate data from all of the systems within our supply chain to ensure no information gets lost or altered as the product moves from farm to lab and ultimately into the hands of the customer,” says Sébastien Pasquali, Head of Information Technology at Mile High Labs.
Not only does blockchain technology help ensure quality for customers but it also helps CBD companies self-regulate in an underregulated market.
While the 2018 Farm Bill created a path towards legal hemp production, there were few measures put in place to regulate products derived from hemp. While further updates from the U.S. Food and Drug Administration are expected over the summer, Mile High Labs continues to implement quality assurance and control processes drawn from the pharmaceutical industry.
CBD in Europe and the UK
As CBD products become more prevalent in Europe and the UK, the Centre for Medicinal Cannabis (CMC) is leading the discussion on regulation and research. Mile High Labs is working alongside CMC to educate stakeholders and the public about CBD and develop a roadmap for strong regulations.
“We’re building global trust in CBD as an effective and safe ingredient,” said John Wallace, Managing Director of UK/EU for Mile High Labs. “Not only customer and consumer trust, but the trust of the regulatory officials that oversee the import and export of CBD ingredients and products.”
By educating our customers and upholding the highest standards for our products, Mile High Labs intends to become the trusted leader in the marketplace on both sides of the Atlantic. You can learn more about our company and the industry by visiting milehighlabs.com or contacting Mile High Labs International Limited at info@milehighlabs.co.uk or +44 (0)28 9099 5253.
Please note: This is a commercial profile
Mile High Labs International Limited
Tel: +44 (0)28 9099 5253
